Age - Related Macular Degeneration (AMD)

Ophthalmology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
1
Intravitreal Aflibercept InjectionPhase 41 trial
Active Trials
NCT01722045Completed154Est. Sep 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RegeneronIntravitreal Aflibercept Injection

Clinical Trials (1)

Total enrollment: 154 patients across 1 trials

NCT01722045RegeneronIntravitreal Aflibercept Injection

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Start: Nov 2012Est. completion: Sep 2015154 patients
Phase 4Completed

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space